论文部分内容阅读
目的探讨重组人p53腺病毒注射液(rAd-p53)与顺铂序贯胸腔灌注联合热疗治疗肺癌胸腔积液的有效性及安全性。方法 101例合并恶性胸腔积液的肺癌患者根据治疗方法分为观察组52例(采用rAd-P53与顺铂序贯胸腔灌注联合热疗),对照组49例(采用顺铂胸腔灌注联合热疗),比较两组患者治疗后近期疗效、生活质量及不良反应。结果治疗后,观察组患者的治疗有效率为80.8%,明显高于对照组的61.2%,差异有统计学意义(P<0.05);观察组患者的生活质量改善率为59.6%,明显高于对照组的38.8%,差异有统计学意义(P<0.05);观察组患者的发热发生率为46.2%,对照组为22.5%,差异有统计学意义(P<0.05),两组患者在消化道反应、骨髓抑制发生率比较差异无统计学意义(P>0.05)。结论重组人p53腺病毒注射液与顺铂序贯胸腔灌注联合热疗具有协同作用,可提高患者的近期疗效,改善患者生活质量。
Objective To investigate the efficacy and safety of recombinant human adenovirus p53 (rAd-p53) and cisplatin combined with sequential pleural perfusion combined with hyperthermia in the treatment of pleural effusion in lung cancer. Methods 101 patients with malignant pleural effusion of lung cancer patients were divided into observation group of 52 patients (using rAd-P53 and cisplatin sequential thoracic perfusion combined with hyperthermia), the control group of 49 patients (with cisplatin and pleural perfusion combined with hyperthermia ). The short-term curative effect, quality of life and adverse reactions of two groups were compared. Results After treatment, the effective rate of treatment in observation group was 80.8%, which was significantly higher than that in control group (61.2%, P <0.05). The improvement rate of quality of life in observation group was 59.6% The difference was statistically significant (P <0.05). The incidence of fever in the observation group was 46.2% and in the control group was 22.5%, the difference was statistically significant (P <0.05) Road reaction, the incidence of bone marrow suppression was no significant difference (P> 0.05). Conclusions Recombinant human p53 adenovirus injection has a synergistic effect with sequential cisplatin and hyperthermia combined with cisplatin, which can improve the short-term curative effect and improve the quality of life of patients.